Blood test may spot infection risk in elderly hip fracture patients

NCT ID NCT07350785

Recruiting now Knowledge-focused Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test marker called Monocyte Distribution Width (MDW) can help predict complications and survival in elderly patients with hip fracture. Researchers will follow 100 patients aged 65 and older, measuring MDW and other inflammatory markers at admission and after surgery. The goal is to see if MDW can identify those at higher risk for infections or death, which could lead to earlier and better care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If MDW proves reliable, doctors could use a simple blood test to identify high-risk hip fracture patients early and provide closer monitoring.
What could go wrong: This is a small observational study, not a treatment trial. MDW may not be accurate enough to change practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIP FRACTURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hip fracture infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIP FRACTURE OSTEOPOROTIC HIP FRACTURE SEPSIS

Contacts and locations

Locations

Laboratory for Research of the Musculoskeletal System
RECRUITING

Kifissia, Attica, 14561, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.